Amendments to the Claims

1.) (original) A binding molecule which is capable of binding to the human NogoA polypeptide (SEQ ID NO: 5) or human NiG (SEQ ID NO: 7) or human NiG-D20 (SEQ ID NO: 24) or human NogoA_623-640 (SEQ ID NO: 6) with a dissociation constant < 1000nM.

2.) (original) A binding molecule which is capable of binding to the human NogoA polypeptide (SEQ ID NO: 5) or human NiG (SEQ ID NO: 7) or human NiG-D20 (SEQ ID NO: 24) or human NogoA_623-640 (SEQ ID NO: 6) with a dissociation constant < 1000nM and comprises at least one antigen binding site, said antigen binding site comprising either

- in sequence the hypervariable regions CDR1, CDR2, and CDR3, of which each of the hypervariable regions are at least 50% homologous to their equivalent hypervariable regions CDR1-11C7 (SEQ ID NO: 8), CDR2-11C7 (SEQ ID NO: 9) and CDR3-11C7 (SEQ ID NO: 10); or
- in sequence the hypervariable regions CDR1', CDR2', and CDR3', of which each of the hypervariable regions are at least 50% homologous to their equivalent hypervariable regions CDR1'-11C7 (SEQ ID NO: 11), CDR2'-11C7 (SEQ ID NO: 12) and CDR3'-11C7 (SEQ ID NO: 13).

3.) (original) A binding molecule which is capable of binding to the human NogoA polypeptide (SEQ ID NO: 5) or human NiG (SEQ ID NO: 7) or human NiG-D20 (SEQ ID NO: 24) or human NogoA_623-640 (SEQ ID NO: 6) with a dissociation constant < 1000nM and comprises

- a first antigen binding site comprising in sequence the hypervariable regions CDR1, CDR2, and CDR3, of which each of the hypervariable regions are at least 50% homologous to their equivalent hypervariable regions CDR1-11C7 (SEQ ID NO: 8), CDR2-11C7 (SEQ ID NO: 9) and CDR3-11C7 (SEQ ID NO: 10); and
- a second antigen binding site comprising in sequence the hypervariable regions CDR1', CDR2', and CDR3', of which each of the hypervariable regions are at least 50% homologous to their equivalent hypervariable regions CDR1'-11C7 (SEQ ID NO: 11), CDR2'-11C7 (SEQ ID NO: 12) and CDR3'-11C7 (SEQ ID NO: 13).

4.) (original) A binding molecule which comprises at least one antigen binding site, said antigen binding site comprising either

- in sequence the hypervariable regions CDR1-11C7 (SEQ ID NO: 8), CDR2-11C7 (SEQ ID NO: 9) and CDR3-11C7 (SEQ ID NO: 10); or
- in sequence the hypervariable regions CDR1'-11C7 (SEQ ID NO: 11), CDR2'-11C7 (SEQ ID NO: 12) and CDR3'-11C7 (SEQ ID NO: 13); or

- direct equivalents thereof.

5.) (original) A binding molecule comprising

- a first antigen binding site comprising in sequence the hypervariable regions CDR1-11C7 (SEQ ID NO: 8), CDR2-11C7 (SEQ ID NO: 9) and CDR3-11C7 (SEQ ID NO: 10); and
- a second antigen binding site comprising in sequence the hypervariable regions CDR1'-11C7 (SEQ ID NO: 11), CDR2'-11C7 (SEQ ID NO: 12) and CDR3'-11C7 (SEQ ID NO: 13); or
- direct equivalents thereof.

6.) (currently amended) The binding molecule according to claims 1 ~~to 5~~ which comprises at least

- one immunoglobulin heavy chain or fragment thereof which comprises (i) a variable domain comprising in sequence the hypervariable regions regions CDR1-11C7 (SEQ ID NO: 8), CDR2-11C7 (SEQ ID NO: 9) and CDR3-11C7 (SEQ ID NO: 10) and (ii) the constant part or fragment thereof of a human heavy chain; and
- one immunoglobulin light chain or fragment thereof which comprises (i) a variable domain comprising in sequence the hypervariable regions CDR1'-11C7 (SEQ ID NO: 11), CDR2'-11C7 (SEQ ID NO: 12) and CDR3'-11C7 (SEQ ID NO: 13) and (ii) the constant part or fragment thereof of a human light chain; or
- direct equivalents thereof.

7. (original) The binding molecule according to claim 6 in which the constant part or fragment thereof of the human heavy chain is of the γ4 type and the constant part or fragment thereof of the human light chain is of the κ type.

8. (currently amended) The binding molecule according to claims 1 ~~to 7~~, which is a chimeric or humanised monoclonal antibody.

9. (original) A binding molecule comprising polypeptide sequences as shown in SEQ ID NO: 2 and SEQ ID NO: 3.

10. (currently amended) A polynucleotide comprising polynucleotides encoding a binding molecule according to any of claims 1 ~~to 9~~.

11. (original) A polynucleotide comprising either

- polynucletide sequences as shown in SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16; or

- polynucletide sequences as shown in SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19.

12. (currently amended) An expression vector comprising polynucleotides according to ~~any one of~~ claims 10 ~~or 11~~.

13. (currently amended) An expression system comprising a polynucleotide according to ~~any one of~~ claims 10 ~~or 11~~, wherein said expression system or part thereof is capable of producing a polypeptide of ~~any one of~~ claims 1 ~~to 9~~, when said expression system or part thereof is present in a compatible host cell.

14. (original) An isolated host cell which comprises an expression system according to claim 13.

15. (currently amended) The use of a binding molecule according to ~~any one of~~ claims 1 ~~to 9~~ as a pharmaceutical.

16. (currently amended) The use of a binding molecule according to ~~any one of~~ claims 1 ~~to 9~~ in the treatment of nerve repair.

17. (currently amended) A pharmaceutical composition comprising a binding molecule according to ~~any one of~~ claims 1 ~~to 9~~ in association with at least one pharmaceutically acceptable carrier or diluent.

18. (currently amended) A method of treatment of diseases associated with nerve repair comprising administering to a subject in need of such treatment an effective amount of a binding molecule according to ~~any one of~~ claims 1 ~~to 9~~.